|
|
|
|
|
Milrinone
drug data and news
Milrinone drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Milrinone | ||
| Brand Names/Synonyms | Corotrop; Corotrope; Milrila; Milrinone; Milrinone Lactate; Milrinone Lactose in 5% Dextrose; Primacor | ||
| Indication | Indicated for the treatment of congestive heart failure. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Milrinone, a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine, is used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. | ||
| Mechanism Of Action | Milrinone inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, Milrinone also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity. | ||
| Milrinone News (When available) |
| ||
| Dosage Forms | LIQUID | ||
| Drug_Category | Vasodilator Agents; Cardiotonic Agents; ATC:C01CE02 | ||
| Absorption | Milrinone is rapidly and almost completely absorbed after oral administration. Bioavailability is 92% (in healthy volunteers). | ||
| Interactions |
-->Interactions for Milrinone: No untoward clinical manifestations have been observed in limited experience with patients in whom PRIMACOR was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements. Chemical Interactions There is an immediate chemical interaction which is evidenced by the formation of a precipitate when furosemide is injected into an intravenous line of an infusion of PRIMACOR. Therefore, furosemide should not be administered in intravenous lines containing PRIMACOR. | ||
| Toxicity | LD50 = 0.3 mg/L in rats | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile | ||
| Chemical Formula | C12H9N3O | ||
| Molecular Weight | 211.219 g/mol | ||
| Smiles String | CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2 | ||
| Melting Point | >300 °C | ||
| Water Solubility | Slightly soluble | ||
| State | Solid | ||
| LogP/Hphobicity | 0.462 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | There are five metabolites but the O-glucuronide represents the major pathway of biotransformation. | ||
| Half Life | 2.3 hours | ||
| Protein Binding [%] | 70 to 80% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.rxlist.com/cgi/generic3/milrin.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00010 | ||
| CAS Registry Number | 78415-72-2 | ||
| KEGG Compound ID | C07224 | ||
| PubChem ID | SID:9433 | ||
| PharmGKB ID | PA450510 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2244811 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |